CS
NTLA icon

Credit Suisse’s Intellia Therapeutics NTLA Stock Holding History

Credit Suisse’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.7M Buy
134,497
+317
+0.2% +$8.8K ﹤0.01% 1468
2023
Q4 		$4.09M Buy
134,180
+12,493
+10% +$359K ﹤0.01% 1455
2023
Q3 		$3.85M Sell
121,687
-3,221
-3% -$125K ﹤0.01% 1420
2023
Q2 		$5.09M Buy
124,908
+22,188
+22% +$900K 0.01% 1324
2023
Q1 		$3.83M Buy
102,720
+10,163
+11% +$399K ﹤0.01% 1491
2022
Q4 		$3.23M Buy
92,557
+9,549
+12% +$454K ﹤0.01% 1599
2022
Q3 		$4.64M Sell
83,008
-888
-1% -$55.1K 0.01% 1297
2022
Q2 		$4.34M Sell
83,896
-15,883
-16% -$807K ﹤0.01% 1378
2022
Q1 		$7.25M Buy
99,779
+28,702
+40% +$2.43M 0.01% 1207
2021
Q4 		$8.4M Sell
71,077
-8,619
-11% -$1.08M ﹤0.01% 1634
2021
Q3 		$10.7M Sell
79,696
-18,581
-19% -$2.81M 0.01% 1492
2021
Q2 		$15.9M Buy
98,277
+17,640
+22% +$1.37M 0.01% 1270
2021
Q1 		$6.47M Sell
80,637
-21,649
-21% -$1.45M ﹤0.01% 1865
2020
Q4 		$5.56M Sell
102,286
-26,087
-20% -$947K ﹤0.01% 2006
2020
Q3 		$2.55M Buy
128,373
+20,737
+19% +$432K ﹤0.01% 2249
2020
Q2 		$2.26M Buy
107,636
+47,181
+78% +$802K ﹤0.01% 2287
2020
Q1 		$739K Buy
60,455
+19,825
+49% +$267K ﹤0.01% 2887
2019
Q4 		$595K Buy
40,630
+15,479
+62% +$215K ﹤0.01% 3453
2019
Q3 		$335K Sell
25,151
-1,063
-4% -$16.9K ﹤0.01% 3646
2019
Q2 		$428K Buy
26,214
+6,215
+31% +$97.7K ﹤0.01% 3491
2019
Q1 		$341K Sell
19,999
-6,639
-25% -$99K ﹤0.01% 3546
2018
Q4 		$363K Buy
26,638
+1,472
+6% +$27.4K ﹤0.01% 3423
2018
Q3 		$721K Sell
25,166
-10,165
-29% -$296K ﹤0.01% 3085
2018
Q2 		$967K Buy
35,331
+5,065
+17% +$123K ﹤0.01% 3028
2018
Q1 		$638K Buy
30,266
+4,390
+17% +$108K ﹤0.01% 3233
2017
Q4 		$498K Buy
25,876
+2,338
+10% +$54K ﹤0.01% 3438
2017
Q3 		$585K Buy
+23,538
New +$443K ﹤0.01% 3455
2017
Q1 		– Sell
-12,379
Closed -$162K – 3980
2016
Q4 		$162K Sell
12,379
-2,061
-14% -$31K ﹤0.01% 3869
2016
Q3 		$245K Buy
+14,440
New +$279K ﹤0.01% 3737

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's NTLA Position: Q1 2024 in Review

Credit Suisse increased its Intellia Therapeutics (NTLA) stake by 0.24% in Q1 2024, buying an estimated $8.8K and bringing the position to 134,497 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

Credit Suisse first reported a position in NTLA in Q3 2016 and has held it in 29 quarters since. The position peaked at $15.9M in Q2 2021. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Credit Suisse held 134,497 shares of Intellia Therapeutics worth $3.7M as of Q1 2024.
  • Credit Suisse bought 317 Intellia Therapeutics shares in Q1 2024, an estimated $8.8K.
  • Intellia Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1468 holding.
  • Credit Suisse first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 29 quarters since.
  • Credit Suisse's Intellia Therapeutics position peaked at $15.9M in Q2 2021.
  • 285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.